First-Choice Treatment in Uncomplicated Ulcer Disease: A Case for Acid Inhibitors
First-Choice Treatment in Uncomplicated Ulcer Disease: A Case for Acid Inhibitors
复制标题
无并发症性溃疡病的首选治疗：酸抑制剂的案例
DOI：
--
复制
发表时间：
1988
期刊：
影响因子：
--
通讯作者：
B. Simon
中科院分区：
文献类型：
--
作者：
Dammann Hg;M. Dreyer;R. Kangah;P. Müller;B. Simon
对于无并发症的溃疡疾病，首选的治疗方法是由主要的治疗目标决定的，即缓解疼痛、迅速愈合、给药形式简单和安全。目前，h2受体拮抗剂可以最好地实现这些目标，在目前可用的抗分泌物质中，h2受体拮抗剂显示出突出和明确的临床疗效和安全性。抗毒蕈素类药物如吡仑西平和前列腺素类似物如米索前列醇的主要缺点是它们的治疗范围狭窄；有效的抗溃疡剂量与产生相关副作用的剂量非常接近。奥美拉唑虽然在酸相关疾病中提供了最佳的临床效果，但至少在理论上也存在一些潜在的风险，如ecl细胞增生。对于h2受体拮抗剂，今天的问题不断出现，即如何通过大量减少白天和夜间的酸度来改善治疗结果。单一的傍晚管理与就寝时间……
First-choice treatment in uncomplicated ulcer disease is determined by the main therapeutic aims, namely pain relief, prompt healing, simple administration form, and safety. Today these goals can be best achieved with H2-receptor antagonists, which, among the antisecretory substances currently available, show a prominent and well-defined clinical efficacy and safety profile. The major disadvantage of antimuscarinics such as pirenzepine and prostaglandin analogs such as misoprostol is their narrow therapeutic range; the effective antiulcer dose is very close to the dose that produces relevant side effects. Omeprazole, although providing the best clinical results in acid-related diseases carries at least theoretically some potential risks, such as ECL-cell hyperplasia. With H2-receptor antagonists, today the question continually arises as to how the therapeutic results could be improved through a substantial reduction of both day- and night-time acidity. A single early evening administration versus bedtime ...